This is the webpage dedicated to the updates of the NEVERMIND project and of the research activity of Labion and its partners.
NEWSLETTER ARCHIVE:
Nov 2022: NEVERMIND newsletter_24
Oct 2022: NEVERMIND newsletter_23
Sep 2022: NEVERMIND newsletter_22
Jul/Aug 2022: NEVERMIND newsletter_21
Jun 2022: NEVERMIND newsletter_20
May 2022: NEVERMIND newsletter_19
Apr 2022: NEVERMIND newsletter_18
Mar 2022: NEVERMIND newsletter_17
Feb 2022: NEVERMIND newsletter_16
Jan 2022: NEVERMIND newsletter_15
Dec 2021: NEVERMIND newsletter_14
Nov 2021: NEVERMIND newsletter_13
Oct 2021: NEVERMIND newsletter_12
Sep 2021: NEVERMIND newsletter_11
Jul/Aug 2021: NEVERMIND newsletter_10
Jun 2021: NEVERMIND newsletter_09
May 2021: NEVERMIND newsletter_08
Apr 2021: NEVERMIND newsletter_07
Mar 2021: NEVERMIND newsletter_06
Feb 2021: NEVERMIND newsletter_05
Jan 2021: NEVERMIND newsletter_04
Dec 2020: NEVERMIND newsletter_03
Nov 2020: NEVERMIND newsletter_02
Oct 2020: NEVERMIND newsletter_01
NEVERMIND RESEARCH ARTICLES:
Giofrè S, Renda A, Sesana S, Formicola B, Vergani B, Leone BE, Denti V, Paglia G, Groppuso S, Romeo V, Muzio L, Balboni A, Menegon A, Antoniou A, Amenta A, Passarella D, Seneci P, Pellegrino S, Re F. Dual Functionalized Liposomes for Selective Delivery of Poorly Soluble Drugs to Inflamed Brain Regions. Pharmaceutics. 2022 Nov 7;14(11):2402. doi: 10.3390/pharmaceutics14112402.
Antoniou AI, Giofrè S, Seneci P, Passarella D, Pellegrino S. Stimulus-responsive liposomes for biomedical applications. Drug Discov Today. 2021 Aug;26(8):1794-1824. doi: 10.1016/j.drudis.2021.05.010. Epub 2021 May 29. PMID: 34058372.
Taiarol L, Formicola B, Fagioli S, Sierri G, D’Aloia A, Kravicz M, Renda A, Viale F, Dal Magro R, Ceriani M, Re F. The 3.0 Cell Communication: New Insights in the Usefulness of Tunneling Nanotubes for Glioblastoma Treatment. Cancers (Basel). 2021 Aug 8;13(16):4001. doi: 10.3390/cancers13164001. PMID: 34439156; PMCID: PMC8392307.
